Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

Koji Izutsu^{1,2} · Michinori Ogura³ · Kensei Tobinai¹ · Kiyohiko Hatake^{4,5} · Shigeru Sakamoto⁶ · Masanori Nishimura⁷ · Miyako Hoshino⁶

Published online: 18 February 2021
© Japanese Society of Hematology 2021

Correction to: International Journal of Hematology
<https://doi.org/10.1007/s12185-020-03039-w>

In the original publication of the article, the affiliation of the corresponding author “Miyako Hoshino” should be changed to “Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan”.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12185-020-03039-w>.

✉ Miyako Hoshino
miyako.hoshino@takeda.com

¹ Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

² Department of Hematology, Toranomon Hospital, Tokyo, Japan

³ Department of Hematology/Oncology, Kasugai Municipal Hospital, Kasugai, Japan

⁴ Department of Hematology, International University of Health and Welfare (IUHW) School of Medicine, Tokyo, Japan

⁵ Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

⁶ Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan

⁷ Pharmacovigilance, Takeda Development Center Japan, Takeda Pharmaceutical Co. Ltd., Osaka, Japan